Rising Bearish Sentiment in NVAX
Recent data from the latest FINRA reporting period indicates a marked increase in bearish positioning against Novavax Inc. (NASDAQ: NVAX). Short interest has risen from 45.66 million shares to 47.49 million shares, a clear signal that institutional and retail traders are increasing their bets against the vaccine developer. This now accounts for approximately 29% of the company's publicly available float.
Liquidity and Squeeze Risk
With an average daily trading volume of roughly 3.38 million shares, the 'days to cover' metric has reached 14.03. This elevated ratio suggests that any positive catalyst could force a rapid covering of these positions, potentially triggering a short squeeze. Investors should monitor the stock closely for volatility, as the high percentage of float held short leaves the equity vulnerable to sharp price swings if sentiment shifts.
Key Takeaways
- Short interest in NVAX has increased to 47.49 million shares.
- The short interest as a percentage of float now stands at 29%.
- The days-to-cover ratio of 14.03 indicates significant potential for a squeeze if the stock rallies.
The Bottom Line
Novavax remains a high-conviction target for short sellers, with nearly a third of its float currently sold short. The high days-to-cover ratio makes this a name to watch for potential volatility.
Signal data sourced from Benzinga. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.